Mydecine Innovations Group (NEOE:MYCO) Accounts Payable & Accrued Expense : C$5.47 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Mydecine Innovations Group Accounts Payable & Accrued Expense?

Mydecine Innovations Group's quarterly accounts payable & accrued expense declined from Mar. 2023 (C$5.26 Mil) to Jun. 2023 (C$4.86 Mil) but then increased from Jun. 2023 (C$4.86 Mil) to Sep. 2023 (C$5.47 Mil).

Mydecine Innovations Group's annual accounts payable & accrued expense increased from Dec. 2020 (C$1.19 Mil) to Dec. 2021 (C$1.59 Mil) and increased from Dec. 2021 (C$1.59 Mil) to Dec. 2022 (C$5.37 Mil).

Mydecine Innovations Group Accounts Payable & Accrued Expense Historical Data

The historical data trend for Mydecine Innovations Group's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Accounts Payable & Accrued Expense Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.10

0.17

1.19

1.59

5.37

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.37	5.37	5.26	4.86	5.47

Mydecine Innovations Group Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Mydecine Innovations Group (NEOE:MYCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (NEOE:MYCO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

MYCOF:USA 0NF0:Germany MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (NEOE:MYCO) Headlines

No Headlines